Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by MJgroweron Jan 18, 2017 11:18am

42 Views

Post# 25722653

RE:RE:RE:To many positives coming with NEWS

Yes I agree, if you are bringing in $100,000 and spending $500,000 there is a problem but if your profit is larger than your expenses and even if you have a debt now as long as you are chipping away at it then it's all good.

Orbital14 wrote: It comes down to how much revenue you are expecting. Profits and revenue are different, lots of cse/tsxv have revenue but arent profitable. If NF became profitable then it would be a game changer

Bullboard Posts

Debt-free cannabis company set for next stage of growth